CStone Pharmaceuticals Initiates Phase III Clinical Trial for Hepatocellular Carcinoma Drug

MT Newswires Live10-02

CStone Pharmaceuticals (HKG:2616) has commenced a Phase III clinical trial for its investigational drug CS1002/SHR-8068 in partnership with Jiangsu Hengrui Pharmaceuticals (SHA:600276), according to a Wednesday filing with the Hong Kong bourse.

The drug is being developed as a potential treatment for advanced hepatocellular carcinoma (HCC).

CStone and Hengrui signed a strategic partnership and exclusive licensing agreement in November 2021 for the drug.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2472259657?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-02 13:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2472259657","market":"fut","top_or_hot":-1,"title":"CStone Pharmaceuticals Initiates Phase III Clinical Trial for Hepatocellular Carcinoma Drug","media":"MT Newswires Live","content":"<html><body><p> CStone Pharmaceuticals (HKG:2616)  has commenced a Phase III clinical trial for its investigational drug CS1002/SHR-8068 in partnership with Jiangsu Hengrui Pharmaceuticals (SHA:600276), according to a Wednesday filing with the Hong Kong bourse.</p><p>The drug is being developed as a potential treatment for advanced hepatocellular carcinoma (HCC).</p><p>CStone and Hengrui signed a strategic partnership and exclusive licensing agreement in November 2021 for the drug.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CStone Pharmaceuticals Initiates Phase III Clinical Trial for Hepatocellular Carcinoma Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCStone Pharmaceuticals Initiates Phase III Clinical Trial for Hepatocellular Carcinoma Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-02 13:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CStone Pharmaceuticals (HKG:2616)  has commenced a Phase III clinical trial for its investigational drug CS1002/SHR-8068 in partnership with Jiangsu Hengrui Pharmaceuticals (SHA:600276), according to ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HCC","symbol_name":"Warrior Met Coal LLC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2472259657","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2472259657","pubTimestamp":1727848166,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CStone Pharmaceuticals   has commenced a Phase III clinical trial for its investigational drug CS1002/SHR-8068 in partnership with Jiangsu Hengrui Pharmaceuticals , according to a Wednesday filing with the Hong Kong bourse.The drug is being developed as a potential treatment for advanced hepatocellular carcinoma .CStone and Hengrui signed a strategic partnership and exclusive licensing agreement in November 2021 for the drug.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","HCC":"Warrior Met Coal LLC","BK1161":"生物科技","BK4006":"钢铁","BK1574":"生物医药B类股","III":"信息服务","02616":"基石药业-B","BK4134":"信息科技咨询与其它服务"},"translate_title":"基石药业启动肝细胞癌药物III期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":0.9,"HCC":1,"III":1,"02616":0.9},"content_text":"CStone Pharmaceuticals (HKG:2616)  has commenced a Phase III clinical trial for its investigational drug CS1002/SHR-8068 in partnership with Jiangsu Hengrui Pharmaceuticals (SHA:600276), according to a Wednesday filing with the Hong Kong bourse.The drug is being developed as a potential treatment for advanced hepatocellular carcinoma (HCC).CStone and Hengrui signed a strategic partnership and exclusive licensing agreement in November 2021 for the drug.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2472259657"}